Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ICCC vs ACHV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: ICCC 4 – 2 ACHV Matrix Metrics: ICCC 6 – 4 ACHV

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICCC vs ACHV
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (ICCC 4 – 2 ACHV)

Columns: Metric · ICCC · ACHV
1. Valuation Multiples ACHV
Forward P/E N/M 35.3x
Trailing P/E 56.6x 35.3x
PEG Ratio N/M 17.68x
EV / Revenue 1.6x N/M
2. Growth & Scale ICCC
Revenue Growth (YoY) +11.5% +0.0%
Earnings Growth (YoY) +259.9% +0.0%
TTM Revenue (USD) $67M N/A
Market Cap $97.7M $692.8M
3. Profitability & Quality ICCC
Gross Margin 40.3% N/A
Operating Margin 15.2% 0.0%
Net Profit Margin 2.6% 0.0%
Return on Equity (ROE) 2.6% -845.0%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) $7.4M -$44M
Cash Flow Margin 11.0% N/A
Net Cash / Leverage $13M Net Debt (0.44x D/E) $46M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 88.3% (23rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ICCC
OpEx & R&D Intensity 25.1% of Rev ($17M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICCC (6) vs ACHV (4)
Institutional Metric ICCC ACHV Criterion Row Edge
Market Capitalization
Scale
$97.7M $692.8M Larger Scale ACHV
Trailing P/E Ratio
Valuation
56.6x 35.3x Lower Multiple ACHV
Forward P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+11.5% +0.0% Higher Growth ICCC
Operating Margin (TTM)
Profitability
15.2% 0.0% Higher Margin ICCC
Net Profit Margin
Profitability
2.6% 0.0% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
2.6% -845.0% Higher ROE ICCC
52-Week Range Position
Momentum
91% ($5–$12) 69% ($3–$9) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
0.24β · 46% Vol 1.73β · 62% Vol Lower Realized Risk ICCC
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
$67M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev 17.68x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.4M ($13M Net Debt (0.44x D/E)) -$44M ($46M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ICCC +12.79 pp
ICCC: +4.29% · ACHV: -8.5%
3M Horizon ACHV +6.82 pp
ICCC: -6.67% · ACHV: +0.15%
6M Horizon ACHV +0.34 pp
ICCC: +20.95% · ACHV: +21.29%
1Y Horizon ICCC +20.9 pp
ICCC: +68.93% · ACHV: +48.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs ACHV. Trailing 12-month operating profitability (ICCC 15.2% vs ACHV 0.0%) and valuation multiples (ICCC N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ICCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin40.3%
Op. Margin15.2%
ROE / Fwd P/E2.6% · N/M
ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ICCC vs ACHV Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. +0.0% YoY).

ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ICCC generates $67M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.

ACHV screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus ACHV (-845.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.